SCHEMBL844447

SCHEMBL844447

CCOC(=O)C=C(CC)N1CCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.44
HCAR2 Q8TDS4 1/20 0.37
TSHR P16473 3/20 0.37
ALDH1A1 P00352 7/20 0.36
HPGD P15428 6/20 0.36
RAB9A P51151 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
NPC1 O15118 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.35
ATM Q13315 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13059165 1.00 NPSR1 (0.44) NPSR1HCAR2TSHRALDH1A1HPGD
SCHEMBL3763246 1.00 NPSR1 (0.44) NPSR1HCAR2TSHRALDH1A1HPGD
SCHEMBL28527852 0.86 NPSR1 (0.42) NPSR1HCAR2TSHRALDH1A1HPGD
SCHEMBL9750618 0.84 L3MBTL1 (0.35) HCAR2ALDH1A1HPGDRAB9AL3MBTL1
SCHEMBL9750616 0.84 L3MBTL1 (0.35) HCAR2ALDH1A1HPGDRAB9AL3MBTL1
SCHEMBL535867 0.80 NPSR1 (0.46) NPSR1HCAR2TSHRALDH1A1HPGD
SCHEMBL106944 0.80 NPSR1 (0.46) NPSR1HCAR2TSHRALDH1A1HPGD
SCHEMBL1778153 0.80 NPSR1 (0.46) NPSR1HCAR2TSHRALDH1A1HPGD
SCHEMBL11719535 0.79 NPSR1 (0.44) NPSR1TSHRALDH1A1HPGDRAB9A
SCHEMBL11548990 0.79 NPSR1 (0.44) NPSR1HCAR2TSHRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279218-A1 ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN-LA ROCHE INC. (US) 2024-08-22 US disclosed
CN-109923113-B Isoxazolyl ether derivatives as GABA A alpha 5 PAM 豪夫迈·罗氏有限公司 2023-10-13 CN disclosed
US-20220411415-A1 ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN-LA ROCHE INC. (US) 2022-12-29 US disclosed
EP-3551627-B1 NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN LA ROCHE (CH) 2022-02-16 EP disclosed
US-11091471-B2 Isoxazolyl ether derivatives as GABAA α5 PAM HOFFMANN-LA ROCHE INC. (US) 2021-08-17 US disclosed
US-20190300516-A1 ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN-LA ROCHE INC. (US) 2019-10-03 US disclosed
EP-2432776-B1 METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS UNIV LAVAL (CA) 2019-09-11 EP disclosed
US-9315521-B2 Pyrimidines as novel therapeutic agents UNIVERSITé LAVAL (CA) 2016-04-19 US disclosed
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITé LAVAL (CA) 2015-08-13 US disclosed
US-9040538-B2 Pyrimidines as novel therapeutic agents UNIVERSITE LAVAL (CA) 2015-05-26 US disclosed
EP-2432776-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS Chlorion Pharma, Inc. (CA) 2012-03-28 EP disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 US disclosed
WO-2010132999-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS CHLORION PHARMA, INC. (CA) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP NPSR1 1771/4885HCAR2 193/4885TSHR 4661/4885
US-20190300516-A1 ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM GABRA5, GABRB1, GABRA1 NPSR1 145/4885HCAR2 160/4885TSHR 522/4885
US-20220411415-A1 ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM GABRA5, GABRB1, GABRA1 NPSR1 145/4885HCAR2 160/4885TSHR 522/4885
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP NPSR1 1771/4885HCAR2 193/4885TSHR 4661/4885
US-11091471-B2 Isoxazolyl ether derivatives as GABAA α5 PAM GABRA5, GABRA1, GABRA3 NPSR1 214/4885HCAR2 270/4885TSHR 335/4885
US-20240279218-A1 ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM GABRA5, GABRB1, GABRA1 NPSR1 145/4885HCAR2 160/4885TSHR 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.